Clinical trials: Fibrosis, Liver
Cirrhosis, Esophageal Varices
Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders
The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol…
- Trial name
- CVL-NR (NCT06594783)
- Testing
- Carvedilol plus endoscopic variceal ligation, Carvedilol alone
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Liver Cirrhosis, Portal Vein Thrombosis
Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors
Portal vein thrombosis (PVT) is a common complication in patients with liver cirrhosis and is associated with increased morbidity due to worsening portal hypertension and hepatic decompensation.
- Trial name
- Thrombosis (NCT07560202)
- Testing
- Abdominal US, Doppler US and abdominal multi-slice computed tomography (MSCT) with contrast was performed
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Elham Ahmed Hassan
Liver Cirrhosis, Variceal Bleeding, Cirrhosis
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients.
- Conditions
- Liver Cirrhosis, Variceal Bleeding, Cirrhosis, Ascites Hepatic, Hepatic Encephalopathy (HE)
- Trial name
- NCT07349654
- Testing
- 6mm balloon dilation, 8mm balloon dilation
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Liver Disease, Cirrhosis
Resting Energy Expenditure in Patients on the Waiting List for Liver Transplantation
Metabolic disorders and malnutrition are well known and have been reported in patients with chronic liver disease, but the relationship of energy metabolism and changes in nutritional status in patients on the waiting list for…
- Trial name
- NCT01761851
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of Minas Gerais
Liver Cirrhosis, Portal Hypertension
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients…
- Trial name
- PORTHEMOST (NCT07439939)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Cirrhosis
Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease
Cirrhosis of the liver is a common clinical chronic progressive liver disease, which is a diffuse liver lesion caused by one or more causes over a long period of time or repeatedly.
- Trial name
- NCT03460795
- Testing
- MSC and Tregs
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Ascites, Hepatic Cirrhosis
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.
- Trial name
- NCT01349348
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 535 people
- Sponsor
- Otsuka Beijing Research Institute
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT04594694
- Testing
- Obeticholic acid, Bezafibrate 200 MG, Bezafibrate 400 MG
- Where
- 33 sites in Australia, Belgium and 15 more
- Volunteers
- 75 people
- Sponsor
- Intercept Pharmaceuticals
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Ascites Hepatic, Cirrhosis, Liver
SGLT-2 Inhibitors in the Treatment of Ascites
The goal of this observational study is to test the efficacy of glyphozines (SGLT-2 inhibitors) in the control of ascites in patients with liver cirrhosis in class A6-B9, according to the Child-Pugh classification, and type 2…
- Conditions
- Ascites Hepatic, Cirrhosis, Liver, Diabete Type 2
- Trial name
- NCT05999773
- Testing
- SGLT2 inhibitor
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- University of Palermo
Beta Thalassemia Major
Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C
Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics.
- Trial name
- NCT02744105
- Testing
- Spirulina
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Primary Biliary Cholangitis
Detection Program for Patients With Primary Biliary Cholangitis Lost in the System
Primary biliary cholangitis (PBC) has been considered a rare disease and its management has been limited by the lack of therapeutic alternatives.
- Trial name
- RESCAT (NCT05919433)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Hospital Mutua de Terrassa
Non-alcoholic Steatohepatitis (NASH)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
- Trial name
- NCT04607655
- Testing
- GB1211
- Sponsor
- Galecto Biotech AB
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients…
- Conditions
- Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NAVIGATE (NCT04365868)
- Testing
- belapectin
- Where
- 156 sites in United States, Argentina and 13 more
- Volunteers
- 357 people
- Sponsor
- Galectin Therapeutics Inc.
Primary Biliary Cirrhosis
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
- Trial name
- NCT02135536
- Testing
- NGM282
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 36 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Liver Cirrhosis
Systemic Inflammation in Liver Cirrhosis
Investigate systemic inflammation in liver cirrhosis patients
- Trial name
- SILC (NCT04850534)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Portal Hypertension, Liver Diseases
Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment
Liver cirrhosis is a chronic disease characterized by a progressive accumulation of fibrosis, loss of liver function and portal hypertension leading to several hemodynamic changes.The exact pathophysiological mechanisms causing…
- Conditions
- Portal Hypertension, Liver Diseases, Liver Cirrhoses, Cirrhosis
- Trial name
- NCT03443934
- Where
- Denmark
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Mobile Health, Liver Cirrhosis
Web-based Mobile Health Application for Patients With Liver Cirrhosis (ReLiver-N App)
This study evaluates the effect of a web-based mobile health application for patients with liver cirrhosis (ReLiver-N App) developed for enhancing patients' activation on the level of patient activation, self-efficacy, and…
- Conditions
- Mobile Health, Liver Cirrhosis, Patient Activation
- Trial name
- ReLiver-NApp (NCT05658393)
- Testing
- ReLiver-N App
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Akdeniz University
Nonalcoholic Steatohepatitis
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
This is a randomized, controlled trial to determine whether Losartan is effective at slowing down, halting or reversing liver fibrosis in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- FELINE (NCT01051219)
- Testing
- Losartan
- Where
- 10 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust